Loading…
This article covers information on IXICO plc.
LON:IXIIXICO plc (AIM: IXI) has reported a stronger-than-expected finish to the year ended 30 September 2025, with double-digit revenue growth and improving commercial momentum in the second half. This is a pre-audit trading update, so the headline figures could see minor tweaks, but the direction of travel looks clear.
At a glance: revenue topped market expectations at £6.5 million, up 13% year-on-year, and the year-end order book closed at £13.8 million after a second-half uptick. Cash strengthened to £3.5 million following an oversubscribed capital raise, while EBITDA loss is expected to be slightly better than anticipated at no more than £1.6 million.
FY25 revenue came in at £6.5 million (2024: £5.8 million), a 13% uplift driven by new contract wins, extensions on existing work, and a broader offering into new verticals. In simple terms, IXICO has landed more work across a wider range of customer needs.
That matters because IXICO operates as an imaging contract research organisation (iCRO) focused on neurological disorders. The more biopharma trials it supports, the more recurring and extension-prone the revenue becomes. The update suggests commercial execution improved across the year, not just a one-off deal spike.
The year-end order book was £13.8 million (2024: £15.3 million). On the face of it, that’s a reduction year-on-year, which tempers the top-line beat. However, the second half tells a more encouraging story.
From £13.1 million at 31 March 2025, the order book rose to £13.8 million at year-end. This H2 increase was built on £4.2 million of new contracts and extensions, offset by £3.3 million of revenue recognised and £0.2 million of small scope and FX adjustments. In other words, IXICO both delivered revenue and replenished its pipeline – a good sign for sustainability.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
23 viewsLikes
No ratings yet
Occasional emails on automation, AI and finance. Unsubscribe any time.
Early FY26 has also started on the front foot, with a further £0.9 million of wins signed since the end of September. That supports management’s message that the acceleration in new work is continuing.
Year-end cash was £3.5 million (2024: £1.8 million). The improvement primarily reflects a £3.7 million (net of fees) fundraise completed in the first half, partially offset by investments in the Company’s I-L-S strategy. The RNS doesn’t spell out the components of I-L-S, but the thrust is clear: IXICO is investing to scale its commercial reach and platform capability in neurodegenerative R&D.
From a retail holder’s perspective, this provides more comfort on near-term liquidity while the company works towards improved operating performance. It also raises the bar for execution: investors will want to see those investments convert into faster order intake and margin progress.
EBITDA (a proxy for operating performance before non-cash items and finance costs) is expected to be no more than a £1.6 million loss, slightly better than market expectations and an improvement on the £1.7 million loss last year. Management links this to double-digit revenue growth, partly offset by targeted growth investments.
In short, IXICO remains in investment mode. The company is prioritising growth – new customers and verticals – over near-term profitability. The next milestone investors will look for is operating leverage as revenue builds: stable costs plus bigger contracts equals narrowing losses.
CEO Bram Goorden’s commentary is notably upbeat, highlighting an “oversubscribed capital raise” and “initial positive signals” that he believes will “translate into a sustained period of growth and value creation”. He also points to biopharma’s intense focus on CNS research, which supports IXICO’s specialism in neurodegenerative disease trials.
Notably: “Failure is not an option. Patients are waiting for solutions, and the biopharma industry is working harder than ever in CNS to develop treatments.” Strong words – and they set a clear expectation that IXICO intends to keep pressing the accelerator.
| Metric | FY25 | FY24/Comparative | Notes |
|---|---|---|---|
| Revenue | £6.5 million | £5.8 million | Up 13%, ahead of market expectations |
| Order book (year-end) | £13.8 million | £15.3 million | Up from £13.1 million at 31 March 2025 |
| H2 new wins and extensions | £4.2 million | Not disclosed | Offset by £3.3 million revenue recognised and £0.2 million adjustments |
| Cash (year-end) | £3.5 million | £1.8 million | Reflects £3.7 million net capital raise and investment in I-L-S strategy |
| EBITDA | Loss no more than £1.6 million | £1.7 million loss | Slightly improved on market expectations |
| Post year-end new wins | £0.9 million | Not applicable | Signed since 30 September 2025 |
IXICO positions itself as a specialist iCRO in neuroscience, using an AI-driven platform to analyse imaging biomarkers for disorders like Alzheimer’s, Huntington’s and Parkinson’s. That focus aligns with the “thriving” neurodegenerative biopharma R&D market referenced by management. You can read more about the company’s platform and background at www.IXICO.com.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.